Leveraging microenvironmental synthetic lethalities to treat cancer
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Treatment resistance leads to cancer patient mortality. Therapeutic approaches that employ synthetic lethality to target mutational vulnerabilities in key tumor cell signaling pathways have proven effective in overcoming therapeutic resistance in some cancers. Yet, tumors are organs composed of malignant cells residing within a cellular and noncellular stroma. Tumor evolution and resistance to anticancer treatment are mediated through a dynamic and reciprocal dialogue with the tumor microenvironment (TME). Accordingly, expanding tumor cell synthetic lethality to encompass contextual synthetic lethality has the potential to eradicate tumors by targeting critical TME circuits that promote tumor progression and therapeutic resistance. In this Review, we summarize current knowledge about the TME and discuss its role in treatment. We outline the concept of tumor cell-specific synthetic lethality and describe therapeutic approaches to expand this paradigm to leverage TME synthetic lethality to improve cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The blood and lymphatic ECs, complex collagen fibers and glycoproteins form the ECM, while the cancer‐associated fibroblasts (CAFs) and mesenchymal stem cells further assist in ECM remodeling and even chemoresistance [13, 14].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Yet many tumors are abnormally and poorly vascularized, which causes nutrient-poor and hypoxic regions within tumors (101).”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Overview of the tumor microenvironment and drug resistance Tumors are composed of a population of cancer cells that are genetically, phenotypically, and spatially heterogeneous, and this heterogeneity correlates with drug resistance (11, 12).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“PARP, BRCA1, and BRCA2 contribute to DNA repair, making cancer cells carrying BRCA mutations more sensitive to PARP inhibitors (97, 98).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“The blood and lymphatic ECs, complex collagen fibers and glycoproteins form the ECM, while the cancer-associated fibroblasts (CAFs) and mesenchymal stem cells further assist in ECM remodeling and even chemoresistance [13, 14].”
BackgroundChen, S., Morine, Y., Tokuda, K., Yamada, S., Saito, Y., Nishi, M., Ikemoto, T., & Shimada, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5239 · Cited by 168
Mechanical state transitions in the regulation of tissue form and function
Mao, Y., & Wickström, S. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00719-x · Cited by 162
Qian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., Xiao, Y., Fuh, K. C., Krishnan, V., Enejder, A. M. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146186 · Cited by 138
“Discussion Accumulating evidence suggests that the tumor microenvironment plays an important role in shaping tumor heterogeneity and drug resistance (65).”
BackgroundPancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis
Saab, J. J. A., Dzierozynski, L. N., Jonker, P. B., AminiTabrizi, R., Shah, H., Menjivar, R. E., Scott, A. J., Nwosu, Z. C., Zhu, Z., Chen, R. N., et al. (2023) · eLife · doi:10.7554/elife.81289 · Cited by 88
“, 2007), we anticipate ensuring proper nutrient availability will be critical in the development of more physiologically relevant ex vivo cancer models, which will expand our ability to target cancer by enabling exploitation of microenvironmentally driven therapeutic targets (Metcalf et al., 2021; Sela et al., 2022).”
Background
Metadata
- Authors
- Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Weaver, Valerie M.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-03-15
- Volume
- 131
- Issue
- 6
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7954586
- OpenAlex
- W3136876771
- Cited by
- 42
- References
- 145
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 5 · 2022: 8 · 2021: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R35CA242447, R01CA227942)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- synthetic lethality, tumor microenvironment, treatment resistance, cancer therapy, tumor stroma, tumor evolution
- MeSH terms
- Synthetic Lethal Mutations, Animals, Female, Humans, Immunotherapy, Male, Neoplasms, Signal Transduction, Disease Progression, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leveraging microenvironmental synthetic lethalities to treat cancer. https://app.cochat.ai/papers/10.1172/jci143765
- The paper
- Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021). Leveraging microenvironmental synthetic lethalities to treat cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci143765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.